PCSK9 and atherosclerosis: The present study demonstrated that the treatment with the anti-PCSK9 antibody mAb1 reduced atherosclerosis development, macrophage infiltration and cardiovascular inflammation and increased the number of EPC and CAC in APOE*3Leiden.CETP mice fed a Western type diet.